clinical trial · NCT07552376
This Study Aims to Evaluate the Efficacy and Safety of QLS1317 in Patients With MSI-H/dMMR Advanced Solid Tumors.
Shanghai Qilu Pharmaceutical Research and Development Center LTD·phase1·not yet recruiting·n = 120
MSI-H or dMMR Advanced Solid TumorsQLS1317
brief summary
The goal of this study aims to evaluate the efficacy and safety of QLS1317 in patients with MSI-H/dMMR advanced solid tumors who failed standard treatment.
started
May 1, 2026
primary completion
Jun 1, 2028
completion
Dec 1, 2028
last updated
Apr 27, 2026
official title
A Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of QLS1317 in Participants With Advanced Solid Tumors Characterized by Microsatellite Instability-High (MSI-H)/Deficient DNA Mismatch Repair (dMMR) Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol